Form D · Biotechnology
VQ Biomedical, Inc.
Apex, NC · CIK 0002062029
Offering snapshot reported Mar 27, 2025 · SEC filing
- Reported sold
- $1.65M Offering amount: $1.65M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 27, 2025 | Initial | $1,650,000 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-542278
Source: Form D, filed Mar 27, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marc Deshusses | Director |
| Daniel E. Estay | Director |
| Joe Knight | Director |
| Galen Robertson | Director, Executive |
| Tobias Straube | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
5448 Apex Peakway Suite 171
Apex, NC, 27502
Apex, NC, 27502